Literature DB >> 21537356

White matter disease: Roles of anti-MOG antibodies in demyelinating diseases.

Tomas Olsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21537356     DOI： 10.1038/nrneurol.2011.45

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children.

Authors:  P H Lalive; M G Häusler; H Maurey; Y Mikaeloff; M Tardieu; H Wiendl; M Schroeter; H P Hartung; B C Kieseier; T Menge
Journal:  Mult Scler       Date:  2010-12-22       Impact factor: 6.312

2.  MHC haplotype-dependent regulation of MOG-induced EAE in rats.

Authors:  R Weissert; E Wallström; M K Storch; A Stefferl; J Lorentzen; H Lassmann; C Linington; T Olsson
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

3.  Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.

Authors:  Franziska Di Pauli; Simone Mader; Kevin Rostasy; Kathrin Schanda; Barbara Bajer-Kornek; Rainer Ehling; Florian Deisenhammer; Markus Reindl; Thomas Berger
Journal:  Clin Immunol       Date:  2010-12-18       Impact factor: 3.969

4.  Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG).

Authors:  U Brehm; S J Piddlesden; M V Gardinier; C Linington
Journal:  J Neuroimmunol       Date:  1999-06-01       Impact factor: 3.478

5.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.

Authors:  Kevin C O'Connor; Katherine A McLaughlin; Philip L De Jager; Tanuja Chitnis; Estelle Bettelli; Chenqi Xu; William H Robinson; Sunil V Cherry; Amit Bar-Or; Brenda Banwell; Hikoaki Fukaura; Toshiyuki Fukazawa; Silvia Tenembaum; Susan J Wong; Norma P Tavakoli; Zhannat Idrissova; Vissia Viglietta; Kevin Rostasy; Daniela Pohl; Russell C Dale; Mark Freedman; Lawrence Steinman; Guy J Buckle; Vijay K Kuchroo; David A Hafler; Kai W Wucherpfennig
Journal:  Nat Med       Date:  2007-01-12       Impact factor: 53.440

6.  Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases.

Authors:  R C Selter; F Brilot; V Grummel; V Kraus; S Cepok; R C Dale; B Hemmer
Journal:  Neurology       Date:  2010-04-21       Impact factor: 9.910

7.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

8.  Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis.

Authors:  E Wallström; M Khademi; M Andersson; R Weissert; C Linington; T Olsson
Journal:  Eur J Immunol       Date:  1998-10       Impact factor: 5.532

9.  Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.

Authors:  Katherine A McLaughlin; Tanuja Chitnis; Jia Newcombe; Bettina Franz; Julia Kennedy; Shannon McArdel; Jens Kuhle; Ludwig Kappos; Kevin Rostasy; Daniela Pohl; Donald Gagne; Jayne M Ness; Silvia Tenembaum; Kevin C O'Connor; Vissia Viglietta; Susan J Wong; Norma P Tavakoli; Jerome de Seze; Zhannat Idrissova; Samia J Khoury; Amit Bar-Or; David A Hafler; Brenda Banwell; Kai W Wucherpfennig
Journal:  J Immunol       Date:  2009-08-17       Impact factor: 5.422

10.  Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease.

Authors:  Fabienne Brilot; Russell C Dale; Rebecca C Selter; Verena Grummel; Sudhakar Reddy Kalluri; Muhammad Aslam; Verena Busch; Dun Zhou; Sabine Cepok; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2009-12       Impact factor: 10.422
  10 in total
  3 in total

Review 1.  Brain-reactive antibodies and disease.

Authors:  B Diamond; G Honig; S Mader; L Brimberg; B T Volpe
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

Review 2.  Nanomedicine strategies for treatment of secondary spinal cord injury.

Authors:  Désirée White-Schenk; Riyi Shi; James F Leary
Journal:  Int J Nanomedicine       Date:  2015-01-29

3.  Antibody-mediated biorecognition of myelin oligodendrocyte glycoprotein: computational evidence of demyelination-related epitopes.

Authors:  Jéssica Cristiane Magalhães Ierich; Doralina Guimarães Brum; Ariana de Souza Moraes; Akemi Martins Higa; Pâmela Soto Garcia; Celina Massumi Miyazaki; Marystela Ferreira; Luís Antonio Peroni; Guedmiller Souza de Oliveira; Eduardo de Faria Franca; Luiz Carlos Gomide Freitas; Fabio Lima Leite
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.